Celecoxib improves disease-free and overall survival in ctDNA-positive stage III colon cancer patients when combined with ...

In another first, Sandoz launched in November 2025 the first FDA-approved biosimilar of Tysabri (natalizumab). Tyruko (natalizumab-sztn) is used to treat adult patients with relapsing multiple ...

The Managed Healthcare Executive 2025 State of the Industry survey is a timely snapshot of how payers, providers and pharmacy ...

Teledermatology's growth in 2025 improved efficiency and accessibility, with virtual visits reducing costs and saving time for patients and doctors. Hybrid models combining live video and photo ...

A study of more than 1 million UK medical records found that getting a flu vaccine between ages 40 and 50 did not increase Parkinson’s disease risk and was even associated with a lower estimated ...

The IRA requires health plans serving the Part D market to cover all negotiated drugs, and it has been predicted that CMS ...

High consumption of ultra-processed foods elevates the risk of early-onset colorectal cancer, highlighting the need for ...

A new Tufts study found that Medicare price negotiations on biologics with imminent biosimilars could lead to near-term savings, but greater savings are likely from biosimilar competition.

Zevaskyn, the first gene therapy for recessive dystrophic epidermolysis bullosa, showed significant wound healing in phase 3 ...

Sanofi is expanding options for those with hemophilia with its new treatment, Qfitlia (fitusiran). Approved this year, ...

Jeff Schaffnit discusses Sanofi's advancements in BTK inhibitors and promising results for hemophilia A therapies at ASH 2025 ...

Venclexta-azacitidine combination offered better responses with less hospitalization and lower symptom burden compared with ...